GERMANTOWN, Md., Feb 17 (Bernama-GLOBE NEWSWIRE) -- Neuralstem, Inc.
(Nasdaq:CUR), a biopharmaceutical company focused on the development of
central nervous system therapies based on its neural stem cell
technology, today announced completion of subject enrollment in its
Phase 2 clinical trial of NSI-189 for the treatment of major depressive
disorder (MDD). NSI-189 is a new chemical entity and the lead compound
in Neuralstem's neurogenic small molecule program. Enrollment was
completed ahead of schedule and data are expected in 3Q 2017.
“Completing the last subject enrolled in the Phase 2 study with NSI-189 for the treatment of MDD earlier than expected is a significant clinical development milestone for Neuralstem,” said Rich Daly, Chairman and CEO, Neuralstem. “We now expect results from the Phase 2 study in the 3Q of 2017, and results from the subsequent, 6-month observational study to assess NSI-189’s durability effect will be available in the first half of 2018. We are thankful to the individuals and physicians who are participating in these studies and helping us to move closer to potentially bringing this new category of treatment forward.”
http://mrem.bernama.com/viewsm.php?idm=28439
“Completing the last subject enrolled in the Phase 2 study with NSI-189 for the treatment of MDD earlier than expected is a significant clinical development milestone for Neuralstem,” said Rich Daly, Chairman and CEO, Neuralstem. “We now expect results from the Phase 2 study in the 3Q of 2017, and results from the subsequent, 6-month observational study to assess NSI-189’s durability effect will be available in the first half of 2018. We are thankful to the individuals and physicians who are participating in these studies and helping us to move closer to potentially bringing this new category of treatment forward.”
No comments:
Post a Comment